Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) Short Interest Up 24.8% in March

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) was the target of a significant growth in short interest during the month of March. As of March 31st, there was short interest totaling 3,494,358 shares, a growth of 24.8% from the March 15th total of 2,799,395 shares. Currently, 6.2% of the shares of the stock are short sold. Based on an average daily trading volume, of 602,528 shares, the short-interest ratio is presently 5.8 days.

Insider Activity

In related news, insider Brian Daniel Webster sold 15,000 shares of the company’s stock in a transaction dated Wednesday, April 15th. The shares were sold at an average price of $20.04, for a total value of $300,600.00. Following the completion of the sale, the insider owned 349,786 shares of the company’s stock, valued at approximately $7,009,711.44. This represents a 4.11% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Insiders have sold a total of 45,000 shares of company stock valued at $988,650 over the last ninety days. Corporate insiders own 3.60% of the company’s stock.

Institutional Investors Weigh In On Kestra Medical Technologies

A number of hedge funds and other institutional investors have recently made changes to their positions in KMTS. Farther Finance Advisors LLC acquired a new position in shares of Kestra Medical Technologies during the 4th quarter valued at about $31,000. Russell Investments Group Ltd. raised its position in Kestra Medical Technologies by 43.5% in the 4th quarter. Russell Investments Group Ltd. now owns 1,563 shares of the company’s stock valued at $41,000 after purchasing an additional 474 shares during the last quarter. China Universal Asset Management Co. Ltd. bought a new position in Kestra Medical Technologies in the 3rd quarter valued at $48,000. Daiwa Securities Group Inc. acquired a new stake in shares of Kestra Medical Technologies in the 4th quarter valued at $72,000. Finally, BNP Paribas Financial Markets increased its stake in shares of Kestra Medical Technologies by 148.9% in the 3rd quarter. BNP Paribas Financial Markets now owns 2,738 shares of the company’s stock valued at $65,000 after buying an additional 1,638 shares during the period.

Analysts Set New Price Targets

Several analysts recently weighed in on KMTS shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Kestra Medical Technologies in a report on Monday, March 23rd. BTIG Research restated a “buy” rating and set a $32.00 target price on shares of Kestra Medical Technologies in a research report on Tuesday, April 7th. Finally, The Goldman Sachs Group lowered their target price on shares of Kestra Medical Technologies from $22.00 to $17.00 and set a “neutral” rating on the stock in a research report on Thursday, April 9th. Three analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $27.40.

Kestra Medical Technologies Trading Up 11.8%

Shares of NASDAQ:KMTS traded up $2.40 during trading on Friday, reaching $22.81. 393,262 shares of the stock were exchanged, compared to its average volume of 405,737. The company has a debt-to-equity ratio of 0.15, a quick ratio of 7.32 and a current ratio of 7.32. Kestra Medical Technologies has a 12-month low of $13.25 and a 12-month high of $30.00. The firm has a market cap of $1.33 billion and a price-to-earnings ratio of -5.76. The firm’s 50-day moving average price is $22.17 and its 200 day moving average price is $24.29.

Kestra Medical Technologies (NASDAQ:KMTS) last announced its earnings results on Tuesday, March 17th. The company reported ($0.61) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.01). Kestra Medical Technologies had a negative net margin of 171.87% and a negative return on equity of 65.49%. The business had revenue of $24.55 million during the quarter. The company’s revenue for the quarter was up 62.7% compared to the same quarter last year.

About Kestra Medical Technologies

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.